Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Reuters NewMedia - November 14, 2008
Gilead said it has 45 days from the receipt of the notification by the U.S. Food and Drug Administration to commence a patent infringement lawsuit against Teva. A lawsuit would restrict approval of the generic drug for up to 30 months or until a court ruling in favor of Teva, whichever occurs first.
Truvada is a combination of Gilead's drugs Viread, known generically as tenofovir, and Emtriva, or emtricitabine.
Gilead said Teva has claimed that two of the patents associated with emtricitabine -- owned by Emory University and licensed Gilead -- are invalid or unenforceable.
The company said Truvada is protected by 10 patents, and all 10 would need to be invalidated or expired before a generic version of Truvada could be marketed.
(Reporting by Deena Beasley; editing by Richard Chang)
081114
RE081115
Copyright © 2008 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .